Extended-release Pharmacotherapy for Opioid Use Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

August 6, 2019

Primary Completion Date

April 29, 2022

Study Completion Date

March 1, 2023

Conditions
Opiate Substitution Treatment
Interventions
DRUG

Buprenorphine Injectable Product

Investigational Medicinal Product

DRUG

Methadone

Standard of Care

DRUG

Buprenorphine

Standard of Care

Trial Locations (5)

Unknown

Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham

NHS Tayside, Dundee

South London and Maudsley NHS Foundation Trust, London

Greater Manchester Mental Health NHS Foundation Trust, Manchester

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne

All Listed Sponsors
collaborator

South London and Maudsley NHS Foundation Trust

OTHER

collaborator

Greater Manchester Mental Health NHS Foundation Trust

OTHER

collaborator

Northumberland, Tyne and Wear NHS Foundation Trust

OTHER

collaborator

Birmingham and Solihull Mental Health NHS Foundation Trust

OTHER

collaborator

NHS Tayside

OTHER_GOV

collaborator

Bangor University

OTHER

lead

King's College London

OTHER

NCT05164549 - Extended-release Pharmacotherapy for Opioid Use Disorder | Biotech Hunter | Biotech Hunter